Renal impairment in patients with multiple myeloma.
نویسندگان
چکیده
OBJECTIVES To determine the incidence of multiple myeloma in the Eastern District of Hong Kong Island, the degree of renal impairment at presentation, and its relationship with haematological and biochemical parameters and survival. DESIGN Retrospective study. SUBJECTS AND METHODS Patients with myeloma who were admitted to a regional hospital in Hong Kong from January 1994 to March 2000 were included. Demographic data, type and stage of multiple myeloma, degree of renal impairment, haematological and biochemical parameters, and survival data were analysed. RESULTS There were 64 patients (28 male, 36 female) in the study. The incidence rate for multiple myeloma in this group was 1.78 per 100 000 population. Immunoglobulin G (53.1%) was the most common type of multiple myeloma seen, followed by immunoglobulin A (29.7%), light-chain (12.5%), and immunoglobulin D (4.7%). Nineteen (29.7%) patients had serum creatinine levels of greater than 177 micro mol/L at presentation. Renal impairment was more common in patients with light-chain multiple myeloma (P=0.081). The serum creatinine level was not significantly correlated with haemoglobin level (r= -0.21), platelet count (r=0.04), serum calcium level (r=0.08), or albumin level (r= -0.03). The median survival time for patients with multiple myeloma was 592 days (95% confidence interval, 229-955). Serum creatinine level at presentation was significantly associated with survival (P=0.017). Patients with a creatinine level of less than 400 micromol/L had longer survival (P=0.042). Infection was the most common cause of death (32.8%). CONCLUSION The incidence rate noted was comparable to other published studies. Renal impairment at presentation was common in patients with multiple myeloma and was associated with poor survival.
منابع مشابه
Mandibular Swelling as the First Manifestation of Multiple Myeloma
Multiple myeloma is a monoclonal malignant proliferation of plasma cells. The disease is more frequent in men, and the average age of patients at the time of diagnosis of the disease is about 60 years. Solitary myeloma may be the first manifestation of the disseminated form of multiple myeloma, which is characterized by multiple skeletal lesions, general metabolic alterations, impairment of ren...
متن کاملRenal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States
Renal impairment is a common complication of multiple myeloma and deterioration in renal function or renal failure may complicate clinical management. This retrospective study in patients with multiple myeloma using an electronic medical records database was designed to estimate the prevalence of renal impairment (single occurrence of estimated glomerular filtration rate [eGFR] <60 mL/min per 1...
متن کاملAn Unusual Presentation of Plasma Cell Leukemia with Undiagnosed Multiple Myeloma
A 54 year old man with history of cardiomyopathy and chronic fibrillation first presented with bloody diarrhea. Then during the assessment of his abnormal lab. data revealed cast nephropathy in renal biopsy, gamma peak in protein electrophoresis and fine lytic lesions in skull graphy. His bone marrow asp...
متن کاملNon Secretory Multiple Myeloma With HCV Infection: A Rare Case Entity
Multiple Myeloma is a neoplasm of B cell lineage characterized by excessive proliferation of abnormal plasma cells. It is characterized by a clinical pentad of 1) anemia, 2) a monoclonal protein in the serum or the urine or both, 3) bone leisons and or bone pain, 4) hypercalcemia >11.5g/dl and 5) renal insufficiency. Non secretory multiple myeloma is a rare variant of the classic form of multi...
متن کاملNovel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Renal impairment is a major complication of multiple myeloma. Patients presenting with severe renal impairment represent a greater therapeutic challenge and generally have poorer outcome. However, once patients with renal impairment achieve remission, their outcomes are comparable with those of patients without renal impairment. Therapies that offer substantial activity in this setting are need...
متن کاملThe Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
BACKGROUND Renal impairment is a common feature in multiple myeloma and is considered a poor prognostic factor. AIM To determine the impact of novel drugs (i.e. bortezomib, lenalidomide and thalidomide) in the treatment of myeloma patients with renal impairment. The primary endpoint was overall survival and secondary endpoints were time to next treatment and response. METHODS The study popu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Hong Kong medical journal = Xianggang yi xue za zhi
دوره 9 2 شماره
صفحات -
تاریخ انتشار 2003